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Abstract 
Hypertension is a risk factor for cardiovascular disease. Increased urinary sodium 
excretion, representing dietary sodium intake, is associated with hypertension. Low 
sodium intake has been associated with increased mortality in observational studies. 
Further studies should assess if confounding relationships explain associations 
between sodium intake and outcomes. We studied UK Biobank participants 
(n=457,484, mean age 56.3 years, 44.7% male) with urinary electrolytes and blood 
pressure data. Estimated daily urinary sodium excretion was calculated using 
Kawasaki formulae. We analysed associations between sodium excretion and blood 
pressure in subjects without cardiovascular disease, treated hypertension or diabetes 
mellitus at baseline (n=322,624). We tested relationships between sodium excretion, 
incidence of fatal and non-fatal cardiovascular disease, heart failure and mortality. 
Subjects in higher quintiles of sodium excretion were younger, with more males and 
higher body mass index. There was a linear relationship between increasing urinary 
sodium excretion and blood pressure. During median follow-up of 6.99 years there 
were 11932 deaths (1125 cardiovascular deaths) with 10717 nonfatal cardiovascular 
events. There was no relationship between quintile of sodium excretion and 
outcomes. These relationships were unchanged after adjustment for comorbidity or 
excluding subjects with events during first two years follow-up. No differing risk of 
incident heart failure (1174 events) existed across sodium excretion quintiles. Urinary 
sodium excretion correlates with elevated blood pressure in subjects at low 
cardiovascular risk. No pattern of increased cardiovascular disease, heart failure or 
mortality risk was demonstrated with either high or low sodium intake. 
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Background 
Hypertension is a modifiable risk factor for development of cardiovascular 
disease (CVD), the leading cause of death in high income countries1, 2. Large cohort 
studies showed associations between high sodium consumption and raised blood 
pressure3-5. Clinical trials have demonstrated that reduction in sodium intake leads to 
lowering of blood pressure6-8 and international guidelines advocate a dietary sodium 
intake of 1.5-2.4g per day9. However, observational cohort studies (in approximately 
3,600 to 102,000 participants) consistently demonstrate J-shaped relationships 
between sodium intake and CVD risk whereby very low sodium intake is associated 
with higher cardiovascular risk10-12. In the PURE study (n ~ 101,945), both low (<3 
g/day) and high (>6 g/day) sodium intakes were associated with higher risk of CVD. 
Some observational data controversially suggest that salt intake relates positively to 
life expectancy13. Thus, conventional dietary guidance on reduction of sodium intake 
conflicts with observational population data regarding CVD risk, even after correction 
for baseline CVD, blood pressure and cholesterol10.  
One explanation often proposed is of ‘reverse causality’ where subjects with 
comorbid conditions (e.g. hypertension, heart failure) have low sodium intake either 
as recommended therapy or are malnourished due to poor dietary (and sodium) 
intake. This explanation becomes less robust in large cohort studies using appropriate 
statistical analysis to account for comorbidities and baseline individual cardiovascular 
risk profile3, 10, 14. We aimed to test if ‘reverse causality’ accounted for ‘J shaped’ 
relationships between sodium intake and CVD and/or mortality.  
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Materials and Methods 
UK Biobank data are available on application to the UK Biobank for data access 
(http://www.ukbiobank.ac.uk/), and authors have returned derived data to UK Biobank 
as per their requirements. Between April 2007 and December 2010, over 500,000 
participants were recruited by UK Biobank, and had baseline measurements recorded 
at one of 22 assessment centres in Scotland, England or Wales, as described 
elsewhere15.  UK Biobank received ethical approval from the North West Multi-center 
Research Ethics Committee (REC reference: 11/NW/03820).  All participants gave 
written informed consent before enrolment, which was conducted in accord with the 
principles of the Declaration of Helsinki.  
 
Ethnicity was coded as white, South Asian, black or other, with white used as the 
referent group.  Body mass index (BMI) was calculated as weight(kg)/height2(m).  
Smoking status was self-reported and categorised as never, former or current smoker, 
and area-based sociodemographic status was derived from postcode of residence, 
using Townsend score16, where higher scores relate to greater deprivation.  Diagnosis 
by a doctor of diabetes mellitus (DM), stroke, myocardial infarction (MI), transient 
ischaemic attack (TIA) or brain haemorrhage were self-reported at baseline. Family 
history of CVD (stroke or heart disease in participant’s mother, father or sibling) was 
self-reported. 
 
A mid-stream urine sample collected was refrigerated between 2 and 8OC until 
potentiometric measurement for sodium and potassium content using a Beckman 
Coulter (UK) Ltd AU5400 analyser. Sodium and potassium concentrations (in mmol/L) 
were capped at sex-specific mean ± 4 standard deviations.  Kawasaki formulae17 were 
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used to convert spot sodium and potassium measurements into estimated 24-hour 
excretion (eNa24h and eK24h, in g/day).  Two resting blood pressure measurements 
were taken, according to a standard operating procedure 
(http://biobank.ctsu.ox.ac.uk/showcase/docs/Bloodpressure.pdf) at least 1 minute 
apart, by trained staff, using either an automated sphygmomanometer with an 
appropriate cuff size relative to the participant’s arm, or manually if an automated 
reading was not possible.  Mean systolic (SBP) and diastolic (DBP) blood pressures 
were calculated and used to derive an estimated mean arterial blood pressure 
(MABP); MABP = (SBP+2*DBP)/3, and pulse pressure PP = (SBP-DBP). Lean body 
mass as fat free mass was derived from whole-body bio-impedance measures using 
the Tanita BC418MA body composition analyser. For full data collection protocols 
refer to UK Biobank online (http://www.ukbiobank.ac.uk). 
The process for generation of the cohort for analysis is shown in figure S1.  Charlson 
co-morbidity index was calculated for all subjects18, and a secondary analysis was 
conducted after excluding those participants with Charlson score greater than zero. 
Use of diuretics and blood pressure medications, were detected by searching 
medicines reported by participants in the 63rd revision of the British National 
Formulary.  
CVD events (MI, stroke, heart failure admission ICD10 codes I20-23, I24.1, I25.2, I60, 
I61, I62, I63 or I64) were identified by linkage with routine hospital data, and date and 
cause of death (where appropriate) were obtained from death certificates held by the 
National Health Service (NHS) Information Centre for participants from England and 
Wales, and the NHS Central Register Scotland for participants from Scotland.  All-
cause mortality (ACM) was defined as death from all causes.  Start of follow-up was 
date of assessment, and end of follow-up for mortality endpoints was recorded as the 
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end of data collection for the assessment centre attended (30/11/2015 for centres in 
Scotland, 31/1/2016 for centres in England/Wales), or date of death, whichever came 
first. For nonfatal outcomes, end of follow-up was date of death, first date of 
hospitalisation for nonfatal CVD, or end of follow-up.  
 
Statistical Analyses 
We excluded participants hospitalised within 30 days of assessment or those missing 
blood pressure measurements from all analyses. Continuous variables (age, BMI (or 
lean body mass), Townsend deprivation score, eNa24h) were summarized as mean ± 
standard deviation or median ± inter-quartile range (Q1, Q3) if the distribution skewed.  
Categorical variables (sex, ethnicity, family history of CVD, smoking status) were 
summarized as numbers and percentages.  MABP and eNa24h were divided into sex-
specific quintiles to lessen impact of outliers. Independent variables were examined 
for differences across quintiles of eNa24h and MABP.  Differences between means or 
groups were tested using ANOVA, Kruskal-Wallis or Pearson’s chi-squared tests for 
Normal, skewed continuous or categorical variables, respectively.    
 
Blood Pressure Models 
Associations of MABP with sex-specific quintiles of eNa24h were examined using sex-
specific unadjusted linear regression models.  Each model was then adjusted for the 
following; age, lean body mass, ethnicity, family history of CVD, smoking status, eK24hr 
and deprivation score.  Linearity of associations were further explored using restricted 
cubic splines (data not shown). 
 
Cardiovascular Disease Models 
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Associations of fatal or nonfatal CVD, or ACM with eNa24h were examined using eNa24h 
in sex-specific quintiles in Cox proportional hazard models.  In these main analyses 
we excluded those with treated hypertension, baseline CVD, or baseline diabetes (Fig 
S1). All models were adjusted for age, Townsend deprivation index, eK24hr, MABP 
(used as continuous variable), smoking status, ethnicity, lean body mass, family 
history of CVD, rheumatoid arthritis, atrial fibrillation and a binary variable for Charlson 
comorbidity score >0. We checked for effect mediation by MABP through models that 
did not adjust for this variable. The proportional hazard assumption was checked by 
visual inspection of Schöenfeld residuals. 
To minimise effect of reverse causality on predictors of early CVD events, we 
performed additional landmark sensitivity analyses, analysing events occurring after 
two years follow up. Further sensitivity analyses were conducted excluding 
participants with Charlson comorbidity index of greater than zero.  
Incident heart failure was treated as specific event of interest, on the basis that excess 
sodium ingestion may lead to sodium and water retention triggering heart failure. Cox 
proportional hazard models used to test for associations with eNa24hr quintiles, using 
the methods as for other CVD events. 
All analyses were performed using STATA 14 (StataCorp LP, College Station, USA). 
A p-value of <0.05 was considered statistically significant.  
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Results 
 
Baseline demographics, blood pressure and urinary sodium excretion in all 
subjects and those without comorbid disease 
Baseline characteristics for all subjects categorised by quintile of MABP are shown in 
Table 1. Subjects in the highest MABP quintiles were more likely to be older, have 
greater BMI and lean body mass, a higher prevalence of family history of CVD, less 
likely to have a positive smoking history, reside in an area of greater socioeconomic 
deprivation and have greater eNa24h excretion. When categorised by quintiles of 
eNa24h excretion (Table 2), subjects in the highest eNa24h quintiles were younger, had 
higher BMI and lean body mass, lower prevalence of family history of CVD, lower 
smoking prevalence, more likely to reside in areas of lower socioeconomic deprivation 
and have higher MABP. Excluding those with treated hypertension, baseline CVD, or 
DM did not substantially attenuate these results (Supplementary Tables S1, S2). In 
regression models assessing relationships between eNa24h and MABP performed in 
subjects without CVD, DM or treated hypertension, there were linear relationships 
between increasing quintiles of eNa24h and increased MABP in both females and 
males (Figure 1). These associations were consistent before and after adjustment for 
baseline characteristics and were similar when restricted to subjects with Charlson 
score of zero to minimise influence of residual confounding.  
 
Relationship between urinary sodium excretion, future CVD events, heart failure 
admissions and all-cause mortality in subjects without baseline CVD 
In 322,624 subjects without baseline CVD, DM and treated hypertension over median 
follow-up time of 6.99 years (IQR 6.29-7.64 years) there were 6742 deaths, 3016 of 
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which were in women (44.7%).  There were 740 fatal CVD events in men and 364 in 
women, and 6972 nonfatal CVD events in men and 3739 in women.  
There was no association between quintiles of eNa24hr and risk of CVD events or ACM 
in any model (Figure 2). These relationships were unaffected by adjustment for self-
reported chronic kidney disease or statin use (Supplementary Figure 2). These 
relationships did not change either after limiting the adjustment model to not include 
MAPB as a potential effect mediator, or following landmark analysis excluding subjects 
who died within 2 years of follow up, or after substituting lean body mass with 
conventional body mass index (Supplementary Figure 3). Data on the incidence of 
subtypes of CVD (myocardial infarction, ischaemic and haemorrhagic stroke) are 
shown in Supplementary Table 3 and Supplementary Figure 4. 
There were 283 incident heart failure hospitalisations during follow up in the 322,624 
participants without baseline CVD, DM or treated hypertension. There were no 
statistically significant differences in risk of incident heart failure across eNa24hr 
quintiles in either males of females (Figure 3). 
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Discussion  
In a large prospective cohort study we demonstrate a consistent relationship between 
estimated urinary sodium excretion as a marker of sodium intake and elevation in 
blood pressure. These relationships were present both in the whole cohort and when 
restricted to subjects free of baseline comorbidity, specified by restricting analysis to 
those without baseline CVD, DM or treated hypertension and with Charlson 
comorbidity score of zero.  These findings are consistent with other cohort studies, 
interventional clinical trials and meta-analyses3-8.   
 The mechanisms by which dietary sodium contribute to raised blood pressure 
have been reviewed extensively elsewhere19. Sodium excess have been associated 
with excess activation of the sympathetic nervous system, increased vascular tone, 
and endothelial dysfunction as well as end organ damage with left ventricular 
hypertrophy, glomerulosclerosis, and arteriolosclerosis. In industrialised countries, 
diets rich in sodium and low in potassium are the norm. Processed meals are rich in 
sodium. Societies following a ‘non-industrialised’ diet low in sodium have very low 
prevalence (<1%) of hypertension20-22. Meta-analyses demonstrate that reduction in 
dietary sodium intake is associated with average reduction in SBP of 3-5.4mmHg in 
hypertensive subjects7, 8. Our data add weight to the hypothesis that reduction of 
dietary sodium intake may lead to lower blood pressure. Unfortunately, we do not have 
long term blood pressure changes to assess the influence of sodium intake on 
development of hypertension. 
The relationship between sodium excretion and future non-fatal CVD and ACM 
is more complex and essentially showed no strong relationship between higher or 
lower sodium intake with risk of mortality or CVD. These null relationships did not 
appear to be altered by adjustment for comorbid disease using the Charlson 
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comorbidity index. The landmark analysis excluding subjects who died within two 
years of follow-up showed similar lack of a relationship between sodium excretion and 
risk of CVD death. This refutes the perception that reverse causality underpins 
relationships whereby those with the lowest sodium intake have greater mortality risk 
due to underlying (perhaps undiagnosed) disease. 
Our results demonstrating a lack of straightforward linear relationships between 
high sodium intake and increased risk of mortality of CVD are broadly in keeping with 
other studies. Whilst much public policy and conventional advice focuses on benefits 
of reduction of sodium intake on future cardiovascular health, large cohort studies, 
including subjects with comorbidities associated with increased CVD risk such as 
chronic kidney disease and diabetes, have demonstrated there is a nadir of sodium 
consumption below which increased risk of future CVD and/or ACM increases12, 23-27. 
Alternatively, lower sodium intake may risk via activation of the renin-angiotensin-
aldosterone system to maintain sodium and water homeostasis exposing the 
cardiovascular system to the deleterious effects of aldosterone28. As heart failure 
represents a syndrome of renal salt avidity driving fluid retention, in the setting of 
cardiac dysfunction29, we specifically analysed the influence of sodium intake on 
incidence of heart failure hospitalisation.  However, we could find no evidence that 
sodium excretion as a marker for sodium intake was associated with incident heart 
failure, albeit in a small number of events. Alternatively, if renal sodium avidity was 
expected to be a driver for future heart failure, one might expect lower sodium 
excretion to precede future heart failure events, but this was not the case. Unlike 
PURE, we do not demonstrate any association with low sodium excretion on CVD 
events or ACM supporting the notion that public health policy reducing sodium intake 
in healthy individuals is not harmful and will be associated reduced blood pressure. It 
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may take longer follow up than this study to demonstrate the benefits of sodium 
reduction on CVD events in low risk individuals.  
Only a large randomised trial of differing sodium intake targets will address what 
the optimal sodium intake should be in an industrialised nation. In the face of public 
health advice, competing pressures from the food industry and trends towards a diet 
based on convenience foods, such a trial would be challenging to implement, and 
would require regular monitoring to ensure participants complied with the ‘prescribed’ 
sodium intake. Experts have designated this such a pressing issue that undertaking 
such a trial in institutionalised environments such as prisons may be justified30.  
There are limitations to this study. The population recruited to UK Biobank were 
volunteers and therefore may not be representative of older or more comorbid 
populations. As observational data, we describe associations, and cannot infer causal 
relationships. We used the Kawasaki formula to estimate daily sodium excretion. 
Estimating sodium excretion from a single urine sample may be inaccurate.  We chose 
to use the Kawasaki formula to allow comparability between studies as it is felt to be 
the least biased of a number of estimation algorithms for estimating 24h sodium 
excretion31. The relationship between sodium and fatal and non-fatal CVD was not in 
keeping with perceived wisdom that lower sodium intake leads to lower risk of CVD. 
Sodium intake was linearly associated with blood pressure, reducing the probability 
that exposure misclassification biased results to the null. The absence of serum 
biochemistry is limitation although out with electrolyte disorders, serum sodium is 
homeostatically maintained in a physiological range in the face of a wide dietary intake. 
There was no assessment of salt sensitivity in this study which would provide more 
detailed insight into which groups are at greater risk from increased dietary salt 
intake32. Finally, recent sodium balance studies demonstrate that relationships 
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between dietary sodium intake and urinary excretion are not as simple as previously 
thought with cyclical handling of sodium over several days and sequestering of sodium 
in organs such as skin and muscle33-36. Whilst this opens new paradigms of thought 
on sodium homeostasis, for large cohort epidemiological research, using estimates of 
sodium intake and excretion from spot urine and derivation from sodium: creatinine 
ratio is widely accepted10, 17. 
 
Perspectives 
In summary, we confirm the relationship between increasing sodium intake and blood 
pressure is linear, but there is a fairly limited relationship between salt intake and risk 
of fatal/non-fatal CVD and ACM in subjects at low cardiovascular risk. Based on these 
observational data from a large cohort, we there is no strong relationship of high or 
low sodium excretion, as a marker of dietary salt intake, with increased risk of 
cardiovascular events or death.  These data may further inform public health debate 
around recommended dietary daily sodium intake. 
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Novelty and significance 
 
1. What is new?  We demonstrate that in a very large cohort of subjects at low 
risk of cardiovascular disease, urinary sodium excretion as a marker for salt 
intake is linearly associated with blood pressure, but with no relationship 
between sodium excretion and cardiovascular events or mortality 
2. What is relevant? Current public health advice to reduce sodium intake is likely 
to lead to lower blood pressure and is unlikely to be harmful in low risk 
individuals. Based on these findings, it is less clear that this has benefits on 
cardiovascular events over follow up of approximately seven years. 
3. Summary. Lower urinary sodium excretion correlated with reduced blood 
pressure in subjects at low cardiovascular risk, but this was not associated with 
reduced cardiovascular events. 
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Figure Legends 
 
Fig 1. Linear regression analyses describing the association between MABP and sex-
specific quintiles of eNa24h in unadjusted (A&C) and fully adjusted models (B&D), using 
all participants (A&B, n=322624), and excluding participants with a Charlson score of 
greater than zero (C&D, n=160920). All plots exclude participants with baseline CVD, 
DM or treated hypertension.  
 
Fig 2. Adjusted hazard ratios of sex-specific quintiles of eNa24h on the risk of all-cause 
mortality (A&B) and fatal or non-fatal cardiovascular disease events (C&D) in all 
participants (A&C, n=322624) and excluding participants with a Charlson score of 
greater than zero (B&D, n=160920). All plots exclude participants with baseline CVD, 
DM or treated hypertension. 
 
Fig 3. Adjusted hazard ratios of sex-specific quintiles of eNa24h on incident heart failure 
in 322624 UK Biobank participants, excluding those with baseline CVD, DM or treated 
hypertension. 
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Factor  MABP mmHg, quintiles P 
  1 2 3 4 5  
 
 
(50.7-
88.7, 
n=51400) 
(48.3-
93.7, 
n=41586) 
(89-95.7, 
n=51218)  
(94-100.3, 
n=41446) 
(96-102, 
n=49240) 
(100.7-
106.3, 
n=40772) 
 
(102.3-110, 
n=51163) 
(106.7-
113.7, 
n=40642) 
 
(110.3-
174.7, 
n=49993) 
(114-177.7, 
n=40024)  
Age 
(years) 
 
52.92 
(8.06) 
54.45 
(8.54) 
55.08 
(8.08) 
55.52 
(8.40) 
56.50 
(7.82) 
56.41 
(8.19) 
57.73 
(7.53) 
57.32 
(7.89) 
58.75 
(7.19) 
58.15 
(7.53) 
<0.0
01 
<0.0
01 
Ethnic 
backgrou
nd 
White 
46785(91
.4) 
37102(89
.8) 
47076 
(92.3) 
37715 
(91.6) 
45242 
(92.2) 
37307 
(92.0) 
47071 
(92.4) 
37466 
(92.7) 
45829 
(92.0) 
37032 
(93.0) 
<0.0
01 
<0.0
01  
Sout
h 
Asian 
735 (1.4) 
957 (2.3) 
677 (1.3) 
807 (2.0) 
677 (1.4) 
758 (1.9) 
653 (1.3) 
673 (1.7) 
679 (1.4) 
545 (1.4)   
Black 
660 (1.3) 
724 (1.8) 
742 (1.5) 
610 (1.5) 
803 (1.6) 
571 (1.4) 
932 (1.8) 
585 (1.4) 
1155 (2.3) 
636 (1.6)   
Other 
3011 
(5.9) 
2553 
(6.2) 
2529 (5.0) 
2057 (5.0) 
2326 (4.7) 
1922 (4.7) 
2274 (4.5) 
1692 (4.2) 
2136 (4.3) 
1610 (4.0)  
Body 
mass 
index 
(kg/m2)  
24.70 
(3.95) 
26.14 
(3.82) 
26.27 
(4.59) 
27.35 
(3.97) 
27.31 
(5.07) 
28.00 
(4.16) 
28.08 
(5.30) 
28.45 
(4.21) 
28.76 
(5.66) 
28.80 
(4.29) 
<0.0
01 
<0.0
01 
Lean 
body 
mass 
(kg)  
43.53 
(4.33) 
62.30 
(7.42) 
44.17 
(4.71) 
63.52 
(7.61) 
44.62 
(5.05) 
63.98 
(7.77) 
44.90 
(5.20) 
64.21 
(7.87) 
45.19 
(5.50) 
64.17 
(7.99) 
<0.0
01 
<0.0
01 
FH CVD 
 
26162(50
.9) 
20451(49
.2) 
28586 
(55.8) 
21184 
(51.1) 
29067 
(59.0) 
21356 
(52.4) 
31471 
(61.5) 
22401 
(55.1) 
31378 
(62.8) 
22367 
(55.9) 
<0.0
01 
<0.0
01 
Smoking 
status 
Neve
r 
30075 
(58.6) 
21726 
(52.3) 
30555 
(59.7) 
21298 
(51.4) 
29646 
(60.3) 
20391 
(50.1) 
30863 
(60.4) 
19975 
(49.2) 
30904 
(61.9) 
19246 
(48.1) 
<0.0
01 
<0.0
01  
Form
er 
15501 
(30.2) 
13564 
(32.7) 
15726 
(30.7) 
14581 
(35.2) 
15237 
(31.0) 
15460 
(38.0) 
16303 
(31.9) 
16092 
(39.6) 
15572 
(31.2) 
16330 
(40.8)   
Curre
nt 
5754 
(11.2) 
6243 
(15.0) 
4887 (9.6) 
5521 (13.3) 
4300 (8.7) 
4873 (12.0) 
3943 (7.7) 
4537 (11.2) 
3475 (7.0) 
4418 (11.0)  
Townsen
d  
-1.25 
(3.08) 
-1.37 (3.02) 
-1.27 (3.15) 
-1.37 (3.02) 
-1.34 (3.10) 
-1.39 (3.01) 
-1.41 (3.07) 
-1.43 (2.99) 
-1.38 (3.07) 
<0.0
01 
 23 
deprivati
on index  
-1.07 
(3.26) 
<0.0
01 
Estimate
d Na24hr 
(g) 
 
3.57 
(2.92, 
4.26) 
4.16 
(3.43, 
4.93) 
3.68 (3.01, 
4.39) 
4.32 (3.60, 
5.08) 
3.75 (3.06, 
4.47) 
4.41 (3.65, 
5.18) 
3.82 (3.11, 
4.56) 
4.46 (3.69, 
5.23) 
3.92 (3.21, 
4.67) 
4.53 (3.75, 
5.31) 
<0.0
01 
<0.0
01 
Rheumat
oid 
Arthritis 
 
563 
(1.1%) 
263 
(0.6%) 
 
656 (1.3%) 
271 (0.7%) 
 
698 (1.4%) 
281 (0.7%) 
 
781 (1.5%) 
291 (0.7%) 
 
831 (1.7%) 
335 (0.8%) 
 
<0.0
01 
0.00
5 
 
Atrial 
Fibrillatio
n 
 
130 
(0.3%) 
302 
(0.7%) 
 
108 (0.2%) 
214 (0.5%) 
 
120 (0.2%) 
224 (0.5%) 
 
116 (0.2%) 
174 (0.4%) 
 
115 (0.2%) 
230 (0.6%) 
 
0.68 
<0.0
01 
 
Baseline 
CVD 
 
3736 
(7.3%) 
6484 
(15.6%) 
 
7459 
(14.6%) 
9208 
(22.2%) 
 
11021 
(22.4%) 
12066 
(29.6%) 
 
16639 
(32.5%) 
15759 
(38.8%) 
 
22991 
(46.0%) 
19520 
(48.8%) 
 
<0.0
01 
<0.0
01 
 
Antihype
rtensive 
medicati
ons 
 
2592 
(5.0%) 
4936 
(11.9%) 
 
5420 
(10.6%) 
7010 
(16.9%) 
 
7984 
(16.2%) 
8884 
(21.8%) 
 
11600 
(22.7%) 
10955 
(27.0%) 
 
13824 
(27.7%) 
11644 
(29.1%) 
 
<0.0
01 
<0.0
01 
 
Diabetes 
Mellitus 
 
1200 
(2.3%) 
2534 
(6.1%) 
 
1755 
(3.4%) 
2777 
(6.7%) 
 
2010 
(4.1%) 
2854 
(7.0%) 
 
2207 
(4.3%) 
2649 
(6.5%) 
 
1894 
(3.8%) 
2128 
(5.3%) 
 
<0.0
01 
<0.0
01 
 
 
Table 1. Distribution of variables by quintiles of MABP in women (upper) and men 
(lower) among all included UK Biobank participants. Numbers in parentheses are 
percentages for ordinal variables, standard deviations for continuous variables, or 
Q1 and Q3 for skewed variables. Tests of differences between groups are χ2and 
One way ANOVA 
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Factor  Estimated Urinary Sodium Excretion g/day, quintiles P 
  1 2 3 4 5  
 
 
(0.71-
2.89, 
n=4783
0) (0.74-
3.43, 
n=3819
3) 
(2.89-
3.48, 
n=47829)
(3.43-
4.08, 
n=38193) 
(3.48-
4.01, 
n=47829)
(4.08-
4.66, 
n=38193) 
(4.01-
4.66, 
n=47829)
(4.66-
5.35, 
n=38193) 
(4.66-7.00, 
n=47829)(
5.35-7.00, 
n=38192)  
Age, 
years 
 
57.37 
(7.88) 
58.10 
(7.86) 
56.45 
(7.93) 
57.11 
(8.05)  
56.07 
(7.95) 
56.43 
(8.18) 
55.84 
(7.98) 
55.77 
(8.22) 
55.31 
(8.07) 
54.71 
(8.32) 
<0.001 
<0.001 
Ethnic 
backgro
und 
White 
44421 
(93.2%) 
34916 
(91.9%) 
44256 
(92.9%) 
35163 
(92.5%) 
44116 
(92.5%) 
35039 
(92.2%) 
43912 
(92.2%) 
35040 
(92.2%) 
43179 
(90.7%) 
34602 
(91.1%) 
<0.001 
<0.001  
South 
Asian 
410 
(0.9%) 
644 
(1.7%) 
464 
(1.0%) 
563 
(1.5%) 
494 
(1.0%) 
606 
(1.6%) 
669 
(1.4%) 
696 
(1.8%) 
1057 
(2.2%) 
787 (2.1%)   
Black 
700 
(1.5%) 
586 
(1.5%) 
765 
(1.6%) 
556 
(1.5%) 
806 
(1.7%) 
587 
(1.5%) 
787 
(1.7%) 
542 
(1.4%) 
804 (1.7%) 
577 (1.5%)   
Other 
2110 
(4.4%) 
1830 
(4.8%) 
2178 
(4.6%) 
1720 
(4.5%) 
2262 
(4.7%) 
1762 
(4.6%) 
2280 
(4.8%) 
1713 
(4.5%) 
2558 
(5.4%) 
2005 
(5.3%)  
Body 
mass 
index 
(kg/m2)   
26.48 
(4.82) 
26.99 
(3.91) 
26.40 
(4.73) 
27.18 
(3.82) 
26.67 
(4.85) 
27.44 
(3.91) 
27.09 
(5.07) 
27.91 
(4.08) 
28.05 
(5.65) 
28.69 
(4.54) 
<0.001 
<0.001 
Lean 
body 
mass by 
impedan
ce (kg)  
43.97 
(4.74) 
62.15 
(7.49) 
43.97 
(4.71) 
62.68 
(7.33) 
44.27 
(4.82) 
63.29 
(7.46) 
44.57 
(4.96) 
64.06 
(7.63) 
45.33 
(5.37) 
65.39 
(8.06) 
<0.001 
<0.001 
Family 
history 
of CVD 
 
28404 
(59.4%) 
20815 
(54.5%) 
27682 
(57.9%) 
20395 
(53.4%) 
27647 
(57.8%) 
20069 
(52.5%) 
27446 
(57.4%) 
19988 
(52.3%) 
27525 
(57.5%) 
19521 
(51.1%) 
<0.001 
<0.001 
Smoking 
status 
Never 
28754 
(60.2%) 
19292 
(50.6%) 
29186 
(61.1%) 
19743 
(51.7%) 
29098 
(60.9%) 
19632 
(51.4%) 
28840 
(60.4%) 
19105 
(50.1%) 
28094 
(58.8%) 
18573 
(48.7%) 
<0.001 
<0.001  
Forme
r 
14917 
(31.2%) 
14051 
(36.8%) 
14539 
(30.4%) 
14025 
(36.7%) 
14692 
(30.7%) 
14018 
(36.7%) 
14788 
(30.9%) 
14332 
(37.6%) 
15151 
(31.7%) 
14528 
(38.1%)   
Curre
nt 
4111 
(8.6%) 
4818 
(12.6%) 
4060 
(8.5%) 
4402 
(11.5%) 
4000 
(8.4%) 
4508 
(11.8%) 
4159 
(8.7%) 
4713 
(12.4%) 
4531 
(9.5%) 
5047 
(13.2%)  
 25 
Townsen
d 
deprivati
on index   
-1.48 
(2.98) 
-1.32 
(3.17) 
-1.50 
(2.96) 
-1.49 
(3.06) 
-1.45 
(2.97) 
-1.44 
(3.05) 
-1.37 
(3.01) 
-1.35 
(3.07) 
-1.16 
(3.11) 
-1.10 
(3.17) 
<0.001 
<0.001 
MABP 
(mmHg) 
 
97.00 
(89.00, 
105.67) 
101.67 
(93.67, 
110.00) 
97.67 
(89.67, 
106.67) 
102.33 
(94.67, 
110.67) 
98.67 
(90.33, 
107.33) 
103.00 
(95.33, 
111.00) 
99.67 
(91.33, 
108.33) 
104.00 
(96.33, 
112.00) 
101.33 
(93.00, 
110.00) 
105.00 
(97.67, 
113.00) 
<0.001 
<0.001 
Rheumat
oid 
Arthritis 
 
803 
(1.7%) 
335 
(0.9%) 
 
579 
(1.2%) 
258 
(0.7%) 
 
636 
(1.3%) 
234 
(0.6%) 
 
542 
(1.1%) 
241 
(0.6%) 
 
727 (1.5%) 
252 (0.7%) 
 
<0.001 
<0.001 
 
Atrial 
Fibrillati
on 
 
138 
(0.3%) 
321 
(0.8%) 
 
105 
(0.2%) 
211 
(0.6%) 
 
97 (0.2%) 
210 
(0.5%) 
 
107 
(0.2%) 
164 
(0.4%) 
 
96 (0.2%) 
161 (0.4%) 
 
0.029 
<0.001 
 
Baseline 
CVD 
 
11807 
(24.7%) 
12497 
(32.7%) 
 
10112 
(21.1%) 
10499 
(27.5%) 
 
10308 
(21.6%) 
10471 
(27.4%) 
 
11176 
(23.4%) 
11194 
(29.3%) 
 
14124 
(29.5%) 
12867 
(33.7%) 
 
<0.001 
<0.001 
 
Antihype
rtensive 
medicati
ons 
 
7741 
(16.2%) 
8670 
(22.7%) 
 
6251 
(13.1%) 
6864 
(18.0%) 
 
6611 
(13.8%) 
6932 
(18.1%) 
 
7476 
(15.6%) 
7571 
(19.8%) 
 
10425 
(21.8%) 
9355 
(24.5%) 
 
<0.001 
<0.001 
 
Diabetes 
Mellitus 
 
1624 
(3.4%) 
2423 
(6.3%) 
 
1410 
(2.9%) 
2075 
(5.4%) 
 
1440 
(3.0%) 
2080 
(5.4%) 
 
1627 
(3.4%) 
2208 
(5.8%) 
 
2145 
(4.5%) 
2792 
(7.3%) 
 
<0.001 
<0.001 
 
 
Table 2. Distribution of variables by quintiles of Na24h in women (upper) and men 
(lower) among all included UK Biobank participants 
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Urinary sodium excretion, blood pressure and risk of future cardiovascular 
disease and mortality in subjects without prior cardiovascular disease  
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Supplementary Tables 
S1. Distribution of variables by quintiles of MABP in women (upper) and men (lower) among UK Biobank participants excluding those with treated 
hypertension, baseline CVD, and DM. 
Factor  MABP mmHg, quintiles P 
  1 2 3 4 5  
  
(50.7-87, n=37820)(50-92.3, 
n=28480) 
(87.3-93.3, n=36881)(92.7-
98.3, n=26560) 
(93.7-99.7, n=39070)(98.7-204, 
n=27100) 
(100-107, n=36156)(104.3-111, 
n=26738) 
(107.3-174.7, n=36708)(111-
175.7, n=27111)  
Age (years)  
52.16 (7.86) 
53.18 (8.32) 
53.88 (7.98) 
53.94 (8.32) 
55.23 (7.90) 
54.73 (8.29) 
56.42 (7.70) 
55.68 (8.11) 
57.97 (7.39) 
57.03 (7.89) 
<0.001 
<0.001 
Ethnic background White 
34444 (91.4%) 
25397 (89.7%) 
33914 (92.3%) 
24205 (91.6%) 
36107 (92.8%) 
24897 (92.5%) 
33534 (93.2%) 
24679 (92.8%) 
34089 (93.3%) 
25195 (93.5%) 
<0.001 
<0.001 
 South Asian 
519 (1.4%) 
598 (2.1%) 
458 (1.2%) 
454 (1.7%) 
473 (1.2%) 
419 (1.6%) 
406 (1.1%) 
415 (1.6%) 
421 (1.2%) 
343 (1.3%)  
 Black 
442 (1.2%) 
492 (1.7%) 
490 (1.3%) 
364 (1.4%) 
493 (1.3%) 
345 (1.3%) 
483 (1.3%) 
330 (1.2%) 
572 (1.6%) 
342 (1.3%)  
 Other 
2263 (6.0%) 
1812 (6.4%) 
1875 (5.1%) 
1393 (5.3%) 
1825 (4.7%) 
1269 (4.7%) 
1575 (4.4%) 
1164 (4.4%) 
1456 (4.0%) 
1061 (3.9%)  
Body mass index 
(kg/m2)  
24.24 (3.54) 
25.48 (3.34) 
25.50 (4.10) 
26.58 (3.51) 
26.32 (4.47) 
27.15 (3.62) 
27.11 (4.79) 
27.63 (3.79) 
27.91 (5.21) 
28.13 (3.96) 
<0.001 
<0.001 
Lean body mass by 
impedance (kg)  
43.35 (4.16) 
62.01 (7.15) 
43.88 (4.44) 
63.13 (7.37) 
44.18 (4.71) 
63.55 (7.45) 
44.47 (4.87) 
63.75 (7.60) 
44.73 (5.19) 
63.67 (7.74) 
<0.001 
<0.001 
Family history of CVD  
18527 (49.0%) 
13204 (46.4%) 
19409 (52.6%) 
12760 (48.0%) 
21731 (55.6%) 
13178 (48.6%) 
20967 (58.0%) 
13704 (51.3%) 
21969 (59.8%) 
14224 (52.5%) 
<0.001 
<0.001 
Smoking status Never 
22265 (58.9%) 
15736 (55.3%) 
22138 (60.1%) 
14483 (54.6%) 
23775 (60.9%) 
14459 (53.5%) 
22007 (60.9%) 
14042 (52.6%) 
22708 (62.0%) 
13795 (51.0%) 
<0.001 
<0.001 
 Former 
11259 (29.8%) 
8503 (29.9%) 
11040 (30.0%) 
8373 (31.6%) 
11764 (30.2%) 
9139 (33.8%) 
11165 (30.9%) 
9537 (35.7%) 
11234 (30.7%) 
10160 (37.5%)  
 Current 
4246 (11.2%) 
4198 (14.8%) 
3657 (9.9%) 
3679 (13.9%) 
3478 (8.9%) 
3450 (12.8%) 
2938 (8.1%) 
3124 (11.7%) 
2707 (7.4%) 
3114 (11.5%)  
Townsend deprivation 
index   
-1.30 (3.05) 
-1.15 (3.20) 
-1.43 (2.99) 
-1.39 (3.08) 
-1.49 (2.96) 
-1.47 (3.01) 
-1.51 (2.93) 
-1.49 (3.01) 
-1.58 (2.91) 
-1.54 (2.97) 
<0.001 
<0.001 
Estimated 24hour 
sodium excretion 
(g/day)  
3.56 (2.92, 4.24) 
4.15 (3.44, 4.91) 
3.66 (3.00, 4.36) 
4.31 (3.61, 5.06) 
3.73 (3.07, 4.42) 
4.39 (3.68, 5.12) 
3.78 (3.11, 4.48) 
4.44 (3.71, 5.19) 
3.87 (3.19, 4.58) 
4.52 (3.77, 5.27) 
<0.001 
<0.001 
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S2. Distribution of variables by quintiles of Na24h in women (upper) and men (lower) among UK Biobank participants excluding those with treated 
hypertension, baseline CVD, and DM. 
Factor  Estimated Urinary Sodium Excretion g/day, quintiles P 
  1 2 3 4 5  
  
(0.7-2.9, n=35488)(0.8-3.5, 
n=25685) 
(2.9-3.5, n=35488)(3.5-4.1, 
n=25685) 
(3.5-4.0, n=35488)(4.1-4.6, 
n=25685) 
(4.0-4.6, n=35488)(4.6-5.3, 
n=25685) 
(4.6-7.0, n=35487)(5.3-7.0, 
n=25685)  
Age (years)  
56.37 (7.98) 
56.81 (8.07) 
55.63 (7.97) 
55.93 (8.18) 
55.16 (7.94) 
55.17 (8.24)  
54.81 (7.96) 
54.31 (8.22) 
53.82 (7.96) 
52.78 (8.10) 
<0.001 
<0.001 
Ethnic background White 
33203 (94.0%) 
23664 (92.7%) 
32988 (93.3%) 
23702 (92.8%) 
32911 (93.1%) 
23627 (92.5%) 
32715 (92.6%) 
23571 (92.3%) 
32186 (91.1%) 
23239 (91.0%) 
<0.001 
<0.001 
 South Asian 
258 (0.7%) 
354 (1.4%) 
301 (0.9%) 
307 (1.2%) 
314 (0.9%) 
356 (1.4%) 
447 (1.3%) 
441 (1.7%) 
754 (2.1%) 
518 (2.0%)  
 Black 
352 (1.0%) 
322 (1.3%) 
482 (1.4%) 
323 (1.3%) 
498 (1.4%) 
365 (1.4%) 
470 (1.3%) 
348 (1.4%) 
439 (1.2%) 
350 (1.4%)  
 Other 
1525 (4.3%) 
1194 (4.7%) 
1593 (4.5%) 
1216 (4.8%) 
1646 (4.7%) 
1192 (4.7%) 
1708 (4.8%) 
1184 (4.6%) 
1934 (5.5%) 
1422 (5.6%)  
Body mass index (kg/m2)  
25.70 (4.34) 
26.22 (3.46) 
25.79 (4.34) 
26.59 (3.46) 
26.02 (4.43) 
26.83 (3.60) 
26.31 (4.60) 
27.22 (3.74) 
27.01 (5.06) 
27.80 (4.08) 
<0.001 
<0.001 
Lean body mass by 
impedance kg  
43.63 (4.51) 
61.66 (7.16)  
43.72 (4.48) 
62.38 (7.12) 
43.98 (4.55) 
62.99 (7.24) 
44.24 (4.70) 
63.70 (7.39) 
44.87 (5.03) 
64.96 (7.81) 
<0.001 
<0.001 
Family history of CVD  
20107 (56.7%) 
13286 (51.7%) 
19563 (55.1%) 
12887 (50.2%) 
19698 (55.5%) 
12689 (49.4%) 
19268 (54.3%) 
12574 (49.0%) 
19061 (53.7%) 
12134 (47.2%) 
<0.001 
<0.001 
Smoking status Never 
21512 (60.7%) 
13761 (53.6%) 
21776 (61.4%) 
14017 (54.6%) 
21809 (61.5%) 
13993 (54.5%) 
21467 (60.6%) 
13643 (53.2%) 
20913 (59.0%) 
13312 (51.9%) 
<0.001 
<0.001 
 Former 
10803 (30.5%) 
8581 (33.4%) 
10604 (29.9%) 
8637 (33.7%) 
10621 (30.0%) 
8534 (33.3%) 
10781 (30.4%) 
8758 (34.1%) 
10961 (30.9%) 
8717 (34.0%)  
 Current 
3133 (8.8%) 
3314 (12.9%) 
3065 (8.6%) 
3008 (11.7%) 
3026 (8.5%) 
3128 (12.2%) 
3199 (9.0%) 
3247 (12.7%) 
3558 (10.0%) 
3612 (14.1%)  
Townsend deprivation 
index   
-1.59 (2.93) 
-1.47 (3.08) 
-1.59 (2.90) 
-1.59 (2.99) 
-1.54 (2.91) 
-1.53 (3.00) 
-1.47 (2.96) 
-1.42 (3.02) 
-1.25 (3.06) 
-1.21 (3.10) 
<0.001 
<0.001 
MABP (mmHg)  
94.67 (87.33, 103.00) 
99.33 (92.00, 107.33) 
95.67 (88.00, 104.00) 
100.33 (93.33, 108.00) 
96.33 (88.67, 104.67) 
101.00 (94.00, 109.00) 
97.00 (89.67, 105.67) 
102.00 (94.67, 109.67) 
98.33 (90.67, 106.67) 
102.67 (95.67, 110.67) 
<0.001 
<0.001 
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S3. Incidence rates for different disease outcomes per 100,000 person years among 
all UK Biobank participants, by quintile of eNa24h. 
Outcome Quintile of 
eNa24h 
Incidence rate 
per 100000 
person years 
Lower 95% 
Confidence 
Interval 
Upper 95% 
Confidence 
Interval 
CVD 1 141.56 127.40 157.29 
 2 127.81 114.41 142.78 
 3 130.36 116.83 145.46 
 4 139.00 125.02 154.54 
 5 121.90 108.90 136.45 
All-cause mortality 1 278.96 258.83 300.65 
 2 215.96 198.35 235.13 
 3 227.96 209.87 247.61 
 4 203.92 186.87 222.52 
 5 209.90 192.64 228.70 
Myocardial 
Infarction 
1 39.14 32.04 47.81 
 2 39.50 32.37 48.19 
 3 41.03 33.76 49.87 
 4 36.45 29.65 44.82 
 5 36.63 29.83 44.99 
Haemorrhagic 
stroke 
1 23.63 28.27 30.57 
 2 23.19 17.89 30.07 
 3 21.10 16.08 27.70 
 4 28.34 22.42 35.82 
 5 27.76 21.93 35.15 
Ischaemic stroke 1 46.50 38.70 55.87 
 2 31.75 25.43 39.64 
 3 34.11 27.54 42.24 
 4 31.59 25.30 39.44 
 5 29.78 23.71 37.40 
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Supplementary figures 
 
 
 
 
S1 Flow Diagram demonstrating generation of the cohort from UK Biobank for the 
whole cohort analyses (Table 1 and 2) and by excluding those with baseline CVD, DM 
or treated hypertension. 
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S2 Adjusted (including chronic kidney disease and statin use) linear regression analyses describing the 
association between MABP and sex-specific quintiles of eNa24h (A) and adjusted hazard ratios of sex-
specific quintiles of eNa24h on the risk of CVD (B) 
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S3 Adjusted hazard ratios of sex-specific quintiles of eNa24h on fatal or non-fatal cardiovascular 
disease events (A, C, E) or all-cause mortality (B, D, F), without adjustment for MABP (A, B, 
n=322624), after exclusion of the first two years of follow-up (C, D, n=322624), and after substituting 
lean body mass with continuous body mass index (E, F, n=322624).  All plots exclude participants 
with baseline CVD, DM or treated hypertension.  
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S4 Adjusted hazard ratios of sex-specific quintiles of eNa24h on the risk of myocardial infarction (A) and 
haemorrhagic stroke (B), and ischaemic stroke (C) in all participants (n=322624). All plots exclude 
participants with baseline CVD, DM or treated hypertension. 
